Aliyah Silver is an Analyst at Catalio Capital Management, LP.
She is currently a Ph.D. candidate in Molecular Microbiology and Immunology at Johns Hopkins University, where she has also completed a M.S. in Applied Biomedical Engineering. Her thesis research uses principles from translational immunology and biomedical engineering to develop novel, immune-modulating proteins and platforms for targeted disease therapy. Aliyah has previously worked as a commercialization academy fellow at Johns Hopkins Technology Ventures and as an immuno-oncology graduate R&D intern at Amgen.
Aliyah earned a B.S. in Biological Sciences from the University of Maryland.